New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

Phase 2 data suggest a survival benefit with Bria-IMT and retifanlimab in heavily pretreated HR-positive metastatic breast ...

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic ...

DESTINY-Breast09 Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive ...

Rapid breast cancer research offers new hope, as discussed by Joyce O’Shaughnessy, MD, regarding HR+/HER2– and HER2+ disease.

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation treatment ...